The global ezetimibe market is anticipated to grow at a CAGR of nearly 5.2% during the forecast period (2022-2028). The ezetimibe drug has been approved for use in children aged 10-17 years with cholesterol levels of 500mg/dL or greater, which had previously been limited to those aged 18 and above. In addition, the market is also growing due to the rising prevalence of cardiovascular diseases, an increase in the number of patients suffering from hypercholesterolemia, and other lipid disorders. Furthermore, ease in availability & dosage forms along with better efficiency as compared to its counterpart drugs available in the market boost the growth of ezetimibe during the forecast period. Ezetimibe is also known as Ezetrol which is used for the treatment of high blood cholesterol when there is a too much of a fatty substance called cholesterol in the blood. It can be taken by children from the age of 10 years and by adults. Furthermore, ezetimibe 10 mg tablet is a small flat solid drug meant for oral administration.
Some major players in the market include Merck & Co. Inc., Novartis International AG, and Glenmark Pharmaceuticals Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in June 2019, Glenmark Pharmaceuticals announced that the company received final approval from the US health regulator Food and Drug Administration (FDA) for Ezetimibe and Simvastatin tablets for the treatment of high levels of cholesterol in the blood. It is the generic version of MSD International’s Vytorin tablets. The approval has been granted for the use of 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg.
For instance, in April 2021, Althera Pharmaceuticals announced that the US Food and Drug Administration (FDA) approved the use of Rosuvastatin/ezetimibe tablets as an adjunct to diet for treatment of elevated LDL in adults with primary nonfamilial hyperlipidemia or homozygous familial hypercholesterolemia. Further, the company said that the once-daily tablet (Roszet, Althera) contains rosuvastatin, a statin for LDL reduction, and ezetimibe, a cholesterol absorption inhibitor.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Ezetimibe Market at: https://orionmarketreports.com/request-sample/?id=95478&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By End-Use
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Merck & Co. Inc., Novartis International AG, and Glenmark Pharmaceuticals Ltd., among others.
A full report Ezetimibe Market of is available at: https://orionmarketreports.com/ezetimibe-market/95478/
Global Ezetimibe Market Report by Segment
By Type
- Branded
- Generic
By End-Use
- Adult
- Children
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
